(19) INDIA

(22) Date of filing of Application :30/11/2024

(43) Publication Date: 03/01/2025

(54) Title of the invention : SUBLINGUAL SPRAY FORMULATION FOR HYPERTENSION MANAGEMENT AND RELATED METHODS

(51) International classification	:A61K9/12, A61K31/4168, A61K31/44, A61K47/10, A61K47/12, A61K47/44
(86) International Application No Filing Date	:NA :NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number Filing Date	:NA :NA
(62) Divisional to Application Number Filing Date	:NA :NA

(71)Name of Applicant:

1)Chitkara University

Address of Applicant: Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ------

2) Chitkara Innovation Incubator Foundation

Name of Applicant: NA Address of Applicant: NA (72)Name of Inventor:

1)Dr. Thakur Gurjeet Singh

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ------

2)Ms. Akanksha Kumari

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ------

3)Dr. Loveleen Kaur

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ------------

(57) Abstract:

ABSTRACT A sublingual spray formulation is described, comprising Clonidine and Amlodipine as active pharmaceutical ingredients, dissolved in a solvent system with polyvinyl alcohol as a solubilizer. The formulation includes water, citric acid as a pH regulator, and a bioadhesive agent, designed to bypass first-pass metabolism for rapid systemic delivery and improved bioavailability. The combination of Clonidine and Amlodipine provides synergistic therapeutic effects, enhancing efficacy and reducing side effects for better blood pressure control. The formulation may also include flavoring agents and preservatives, ensuring stability and patient compliance. Reference Fig 1

No. of Pages: 16 No. of Claims: 10